Last reviewed · How we verify
Hydroxethyl starch
Hydroxyethyl starch (HES) is a synthetic colloid that expands intravascular volume by increasing plasma oncotic pressure to maintain fluid balance during hemorrhage or hypovolemia.
Hydroxyethyl starch (HES) is a synthetic colloid that expands intravascular volume by increasing plasma oncotic pressure to maintain fluid balance during hemorrhage or hypovolemia. Used for Acute hypovolemia and hemorrhagic shock requiring volume replacement, Perioperative fluid management in surgical patients.
At a glance
| Generic name | Hydroxethyl starch |
|---|---|
| Sponsor | University Hospital, Clermont-Ferrand |
| Drug class | Synthetic colloid / Plasma volume expander |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Perioperative Medicine |
| Phase | Phase 3 |
Mechanism of action
HES is a glucose polymer derivative that remains in the intravascular space longer than crystalloid solutions, providing sustained volume expansion and improved hemodynamic stability. It is used as a plasma volume expander in acute blood loss and perioperative settings to restore circulating blood volume and maintain tissue perfusion without the need for immediate blood transfusion.
Approved indications
- Acute hypovolemia and hemorrhagic shock requiring volume replacement
- Perioperative fluid management in surgical patients
Common side effects
- Acute kidney injury
- Coagulopathy / increased bleeding
- Hyperchloremic acidosis
- Anaphylaxis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydroxethyl starch CI brief — competitive landscape report
- Hydroxethyl starch updates RSS · CI watch RSS
- University Hospital, Clermont-Ferrand portfolio CI